2. Signaling Pathways
  3. Metabolic Enzyme/Protease
    Vitamin D Related/Nuclear Receptor
  4. ROR

ROR

RAR-related orphan receptor

ROR

Related Products

PDF 0.78 MB

Retinoic acid receptor-related orphan receptors (RORs) are a subfamily of the thyroid hormone receptor, which is a subfamily of the nuclear receptors and belonging to the orphan nuclear receptor family. The ROR subfamily contains three members: RORα (NR1F1), RORβ (NR1F2), and RORγ (NR1F3) and function as ligand-dependent transcription factors.

RORs are reported to activate transcription through ligand-dependent interactions with co-regulators and are involved in the development of secondary lymphoid tissues, autoimmune diseases, inflammatory diseases, the circadian rhythm, and metabolism homeostasis.

RORα and RORγ are important regulators of the immune system. The development and differentiation of Th17 cells are dependent on these factors. RORγ is expressed in lymphoid tissue inducer cells, innate lymphoid cells, invariant natural killer T cells, and γδ T cells, which contribute to inflammation and autoimmune disease.

ROR Isoform Specific Products:

ROR Isoform Comparison
Cat. No. Product Name Effect Purity Chemical Structure
  • HY-115879
    SHR168442
    		Modulator
    SHR168442 is a modulator of retinoid-related orphan receptor gamma (RORγ) with an IC50 value of 0.035 μM.
    SHR168442
  • HY-122737
    RORγt Inverse agonist 8
    		Antagonist
    RORγt Inverse agonist 8 is a potent, selective, orally bioavailable RORγt inverse agonist, with an IC50 of 19 nM for human RORγt-LBD.
    RORγt Inverse agonist 8
  • HY-176273
    RORγt inverse agonist 35
    		Agonist
    RORγt inverse agonist 35 (Compound 22) is a RORγt inverse agonist with an IC50 of 1.51 μM. RORγt inverse agonist 35 significantly inhibits Th17 differentiation and proinflammatory properties in human CD4+ T cells. RORγt inverse agonist 35 can be used for research of Th17-driven autoimmune diseases, such as psoriasis, multiple sclerosis, and inflammatory bowel disease (IBD).
    RORγt inverse agonist 35
  • HY-142940
    RORγt modulator 5
    		Modulator
    RORγt modulator 5 is a RORγt modulator with a Ki value of <100 nM. RORγt modulator 5 has the potential for inflammatory, metabolic, autoimmune and other diseases mediated by RORy study (WO2017132432A1; compound 2).
    RORγt modulator 5
  • HY-155542
    RORγ antagonist 1
    		Antagonist
    RORγ antagonist 1 (compound 22), a potent betulinic acid derivative, is an antagonist of RORγ (KD=0.18 μM). RORγ antagonist 1 exhibits anti-proliferative activity in HPAF-II pancreatic cancer xenograft model. RORγ antagonist 1 inhibits RAS/MAPK and AKT/mTORC1 pathway, and induces caspase-dependent apoptosis in pancreatic cancer cells.
    RORγ antagonist 1
  • HY-RS12126
    RORA Human Pre-designed siRNA Set A
    		Inhibitor

    RORA Human Pre-designed siRNA Set A contains three designed siRNAs for RORA gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
    RORA Human Pre-designed siRNA Set A
    RORA Human Pre-designed siRNA Set A
  • HY-102075B
    TMP780
    		Antagonist 99.51%
    TMP780 is an inverse agonist of RORγt with an IC50 of 13 nM. RORγt is a tractable agent target for the treatment of cutaneous inflammatory disorders.
    TMP780
  • HY-125801R
    3-Oxo-5β-cholanoic acid (Standard)
    		Inhibitor
    3-Oxo-5β-cholanoic acid (Standard) is the analytical standard of 3-Oxo-5β-cholanoic acid. This product is intended for research and analytical applications. 3-Oxo-5β-cholanoic acid (Dehydrolithocholic acid), a bile acid metabolite, inhibits the diferentiation of TH17 cells by directly binding to the key transcription factor RORγt (Kd=1.13 μM)[1].
    3-Oxo-5β-cholanoic acid (Standard)
  • HY-163612
    XY077
    		Agonist
    XY077 (compound 14a) is a RORγ inverse agonist with the IC50 of 0.004 μM. XY077 induces cell apoptosis and shows antiproliferative activity in vivoand in vitro.
    XY077
  • HY-176190
    ROR1-IN-2
    		Inhibitor
    ROR1-IN-2 (compound 9I) is a potent and selective ROR1 inhibitor. ROR1-IN-2 exhibits antiproliferative activity in multiple cancer cells. ROR1-IN-2 significantly suppresses tumor growth in vivo.
    ROR1-IN-2
  • HY-142937
    RORγt agonist 2
    		Agonist
    RORγt agonist 2 is a potent agonist of RORγt. RORγt agonist 2 promotes the differentiation of Th17 cells and enhances the levels of pro-inflammatory cytokines, thereby increasing the cytotoxicity of lymphocytes. RORγt agonist 2 inhibits the production of regulatory T cells, which suppresses the immune response (extracted from patent WO2021136339A1, compound 17).
    RORγt agonist 2
  • HY-142843
    RORγt/DHODH-IN-1
    		Inhibitor
    RORγt/DHODH-IN-1 (compound (R)-14d) is a potent and orally active dual RORγt/DHODH inhibitor, with IC50s of 0.083 μM and 0.172 μM, respectively. RORγt/DHODH-IN-1 exhibits remarkable in vivo anti-inflammatory activity.
    RORγt/DHODH-IN-1
  • HY-142935
    RORγt modulator 2
    		Modulator
    RORγt modulator 2 (Compound 21) is a modulator of retinoid-related orphan receptor γt (RORγt) with the IC50 of <50 nM. RORγt modulator 2 can be used for the research of RORyt mediated diseases such as, e.g., pain, inflammation, COPD, asthma, rheumatoid arthritis, colitis, multiple sclerosis, psoriasis, neurodegenerative diseases and cancer.
    RORγt modulator 2
  • HY-100084
    Methyl-3β-hydroxycholenate
    		Modulator
    Methyl-3β-hydroxycholenate is a ROR gamma modulator extracted from patent US20110263046 A1, in figure 2.
    Methyl-3β-hydroxycholenate
  • HY-142703
    RORγt inverse agonist 28
    		Inhibitor
    RORγt inverse agonist 28 is a potent reverse agonist of RORγt. RORγt inverse agonist 28 regulates the differentiation of Th17 cells and inhibits the production of IL-17. RORγt inverse agonist 28 has the potential for the research of inflammation and autoimmune diseases (extracted from patent WO2021228215A1, compound 6) .
    RORγt inverse agonist 28
  • HY-142939
    RORγt modulator 4
    		Modulator
    RORγt modulator 4 is a RORγt modulator. RORγt modulator 4 has an activity to modulate IL-17A production in cells derived from mouse spleen (WO2018030550A1; compound 146).
    RORγt modulator 4
  • HY-142847
    RORγt/DHODH-IN-3
    		Inhibitor
    RORγt/DHODH-IN-3 (compound (S)-14d) is a dual RORγt/DHODH inhibitor, with IC50s of 0.098 μM and 0.432 μM, respectively. RORγt/DHODH-IN-3 exhibits remarkable in vivo anti-inflammatory activity.
    RORγt/DHODH-IN-3
  • HY-RS12133
    Rorc Mouse Pre-designed siRNA Set A
    		Inhibitor

    Rorc Mouse Pre-designed siRNA Set A contains three designed siRNAs for Rorc gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
    Rorc Mouse Pre-designed siRNA Set A
    Rorc Mouse Pre-designed siRNA Set A
  • HY-RS12127
    Rora Mouse Pre-designed siRNA Set A
    		Inhibitor

    Rora Mouse Pre-designed siRNA Set A contains three designed siRNAs for Rora gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
    Rora Mouse Pre-designed siRNA Set A
    Rora Mouse Pre-designed siRNA Set A
  • HY-142834
    RORγt/DHODH-IN-2
    		Inhibitor
    RORγt/DHODH-IN-2 (compound 1) is a potent dual RORγt/DHODH inhibitor. RORγt/DHODH-IN-2 can be used for inflammatory bowel disease (IBD) research.
    RORγt/DHODH-IN-2
Cat. No. Product Name / Synonyms Application Reactivity
ROR Isoform Comparison

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.